Pre-Surgical Imfinzi Combo Increases Cancer Eradication Chances in Trial

Pre-Surgical Imfinzi Combo Increases Cancer Eradication Chances in Trial
Treating high-risk, HER2-negative breast cancer patients before surgery with the immunotherapy Imfinzi (durvalumab) plus Lynparza (olaparib) and chemotherapy increases the probability for complete cancer eradication, according to the results from a Phase 2 trial. The results showed the triple combination increased the likelihood of cancer eradication from the breast and lymph nodes when compared with chemotherapy alone. Lajos Pusztai, MD, DPhil, professor of medical oncology at Yale University, in Connecticut, presented the results in “Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL." The presentation was given at the American Association for Cancer Research (AACR) Virtual Annual Meeting, held online June 22-24. Breast cancers are often classified by the presence or absence of three receptors: an estrogen receptor (ER), a progesterone receptor, and the Human Epidermal Growth Factor Receptor 2 (HER2). Tumors that lack expression of all three receptors are called triple-negative breast cancer (TNBC). The multicenter Phase 2 I-SPY 2 trial (
Subscribe or to access all post and page content.